Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype by Tatton-Brown, K. (Katrina) et al.
RESEARCH ARTICLEWeaver Syndrome and EZH2 Mutations:
Clarifying the Clinical Phenotype
Katrina Tatton-Brown,1* Anne Murray,1 Sandra Hanks,1 Jenny Douglas,1 Ruth Armstrong,2
Siddharth Banka,3 Lynne M. Bird,4 Carol L. Clericuzio,5 Valerie Cormier-Daire,6 Tom Cushing,5
Frances Flinter,7 Marie-Line Jacquemont,8 Shelagh Joss,9 Esther Kinning,9 Sally Ann Lynch,10
Alex Magee,11 Vivienne McConnell,11 Ana Medeira,12 Keiichi Ozono,13 Michael Patton,14
Julia Rankin,15 Debbie Shears,16 Marleen Simon,17 Miranda Splitt,18 Volker Strenger,19
Kyra Stuurman,20 Clare Taylor,21 Hannah Titheradge,22 Lionel Van Maldergem,23 I. Karen Temple,24
Trevor Cole,22 Sheila Seal,1 Childhood Overgrowth Consortium, and Nazneen Rahman1
1Division of Genetics & Epidemiology, Institute of Cancer Research, Sutton, UK
2Department of Medical Genetics, Addenbrooke’s Hospital, Cambridge, UK
3Centre for Genetic Medicine, Institute of Human Development, University of Manchester, Manchester, UK
4University of California, San Diego, and Rady Children’s Hospital, San Diego, California
5Pediatric Genetics, University of New Mexico, Albuquerque, New Mexico
6Department of Medical Genetics, Hopital Necker Enfants Malades, Paris, France
7Clinical Genetics, Guy’s and St Thomas’ Foundation Trust, London, UK
8Unite´ de Ge´ne´tique Me´dicale, CHU La Re´union, Re´union, France
9Clinical Genetics, West of Scotland Genetics Service, Glasgow, UK
10National Centre for Medical Genetics, Dublin, The Republic of, Ireland
11Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, Northern Ireland, UK
12Servico de Genetica, Hospital S Maria, Lisbon, Portugal
13Department of Developmental Medicine (Pediatrics), Osaka University Graduate School of Medicine, Osaka, Japan
14Medical Genetics, St George’s University of London, London, UK
15Peninsula Clinical Genetics Service, Royal Devon and Exeter Foundation NHS Trust, Exeter, UK
16Department of Clinical Genetics, Churchill Hospital, Oxford, UK
17Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands
18Institute of Human Genetics, International Centre for Life, Newcastle upon Tyne, UK
19Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
20Department of Clinical Genetics, VU University Medical Centre, Amsterdam, The Netherlands
21Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK
22West Midlands Regional Genetics Service, Birmingham Women’s Hospital, Birmingham, UK
23Centre de Ge´ne´tique Humaine, Universite´ de Franche-Comte´, Besanc¸on, France
24Human Genetics and Genomic Medicine, Faculty of Medicine, University of Southampton, Southampton, UKManuscript Received: 26 April 2013; Manuscript Accepted: 8 August 2013Correspondence to:
Dr. Kate Tatton-Brown, Division of Genetics & Epidemiology, Institute
of Cancer Research, Sutton, UK.
E-mail: kate.tatton-brown@icr.ac.uk
Article first published online in Wiley Online Library
(wileyonlinelibrary.com): 8 November 2013
DOI 10.1002/ajmg.a.36229Weaver syndrome, first described in 1974, is characterized by tall
stature, a typical facial appearance, and variable intellectual
disability. In 2011, mutations in the histone methyltransferase,
EZH2, were shown to cause Weaver syndrome. To date, we have
identified 48 individuals with EZH2 mutations. The mutations
were primarily missense mutations occurring throughout
the gene, with some clustering in the SET domain (12/48).2013 Wiley Periodicals, Inc. 2972
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TATTON-BROWN ET AL. 2973Truncating mutations were uncommon (4/48) and only identi-
fied in the final exon, after the SET domain. Through analyses of
clinical data and facial photographs of EZH2mutation-positive
individuals, we have shown that the facial features can be subtle
and the clinical diagnosis of Weaver syndrome is thus challeng-
ing, especially in older individuals. However, tall stature is very
common, reported in>90% of affected individuals. Intellectual
disability is also common,present in80%,but ishighlyvariable
and frequentlymild. Additional clinical features whichmay help
in stratifying individuals to EZH2 mutation testing include
camptodactyly, soft, doughy skin, umbilical hernia, and a low,
hoarse cry. Considerable phenotypic overlap between Sotos and
Weaver syndromes is also evident. The identification of an EZH2
mutationcan thereforeprovide anobjectivemeansof confirming
a subtle presentation ofWeaver syndrome and/or distinguishing
Weaver and Sotos syndromes. As mutation testing becomes
increasingly accessible and larger numbers of EZH2 mutation-
positive individuals are identified, knowledge of the clinical
spectrum and prognostic implications of EZH2 mutations
should improve.  2013 Wiley Periodicals, Inc.
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ferasesINTRODUCTION
Weaver et al. [1974] described two boys with accelerated osseous
maturation, unusual facies, and camptodactyly and proposed that
this constellation of phenotypic features constituted a novel clinical
entity. Subsequent to this initial description over 50 individuals
with similar and additional clinical features were reported and the
condition became eponymously known as Weaver syndrome
(OMIM 277590) [Majewski et al., 1981; Meinecke et al., 1983;
Roussounis and Crawford, 1983; Tsukahara et al., 1984; Farrell
and Hughes, 1985; Ardinger et al., 1986; Thompson et al., 1987;
Greenberg et al., 1989; Kondo et al., 1990, 1991; Muhonen and
Menezes, 1990; Ramos-Arroyo et al., 1991; Cole et al., 1992; Dumic
et al., 1993; Scarano et al., 1996; Fryer et al., 1997; Proud et al., 1998;
Derry et al., 1999; Freeman et al., 1999; Sarigul et al., 1999; Kelly
et al., 2000; Ozkan and Bereket, 2000; Huffman et al., 2001;
Crawford and Rohan, 2005; Coulter et al., 2008; Iatrou et al.,
2008; Bansal and Bansal, 2009; Basel-Vanagaite, 2010; Mikalef
et al., 2010]. However, because of the subtlety of the Weaver
syndrome phenotype and the overlap with other overgrowth
syndromes, particularly Sotos syndrome, the clinical diagnosis
can be challenging, even for the experienced dysmorphologist.
Thus the robustness of the many reported Weaver syndrome
clinical associations is unclear.
In 2011, we and another independent group reported that
constitutional EZH2 mutations cause Weaver syndrome [Gibson
et al., 2011; Tatton-Brown et al., 2011]. EZH2 (Enhancer of Zeste
homolog 2) is located at 7q36.1 and encodes a histone methyl-
transferase involved in chromatin modeling and transcriptional
repression. In combination with EED (Embryonic Ectoderm
Developmentprotein,mouse, homologof) andSUZ12(Suppressorof Zeste 12, drosophila, homolog of), it forms the polycomb
repressive complex 2 (PCR2) which catalyzes the methylation of
lysine residue 27 of histone 3 (H3K27) resulting in chromatin
compaction and repression of transcription [Cao et al., 2002].
EZH2 activity is inhibited by AKT (v-akt murine thymoma viral
oncogene homolog 1), a key component of thePI3K/mTORgrowth
regulatory pathway, through the phosphorylation of serine 21,
which blocks binding of EZH2 to histone 3 [Cha et al., 2005].
Somatic activating and inactivating mono- and biallelic EZH2
mutations have been identified in multiple hematological malig-
nancies [Chase andCross, 2011].A recurrentmonoallelic activating
Tyr646 mutation has been identified in lymphomas, particularly
diffuse large cell B-cell type and follicular lymphomas [Morin
et al., 2010; Sneeringer et al., 2010]. In contrast, inactivating
mono- and biallelic missense and truncating mutations, through-
out EZH2, are associated with poor prognosis myelodysplastic and
myeloproliferative neoplasms [Ernst et al., 2010].
In our initial 2011 paper on EZH2 and Weaver syndrome we
described 19 individuals with EZH2 mutations [Tatton-Brown
et al., 2011]. Subsequent to this study we have extended our
molecular and clinical analyses to identify, in total, 48 individuals
with EZH2mutations from 39 unrelated families. Using data from
these cases, we have defined the EZH2 mutational spectrum
and provide the first detailed evaluation of the clinical features
associated with EZH2-related Weaver syndrome.PATIENTS AND METHODS
Case Series
The research was approved by the London Multicentre Research
Ethics Committee and consent was obtained from participating
individuals and/or their parents. Individuals recruited to the
Childhood Overgrowth Genetics (COG) study with variable
overgrowth phenotypes were screened for mutations in EZH2.
Forty-eight individuals, 20 males and 28 females, with EZH2
mutations (termed EZH2 mutation-positive individuals) were
identified. The patients had been recruited from Clinical Genetics
2974 AMERICAN JOURNAL OF MEDICAL GENETICS PART Acentersworldwide and included25 fromtheUK; 10 fromtheUSA; 3
from France; 2 from the Netherlands; 2 from Portugal; 2 from
the Reunion Islands, and 1 from each of Austria, Belgium, the
Republic of Ireland, and Japan. Clinical information, in the form
of a standardized overgrowth questionnaire (routinely sent to
recruiting physicians) and an EZH2-specific supplementary ques-
tionnaire,was requested for allEZH2mutation-positive individuals
(see Fig. S1). Photographs were additionally received for 43 of the
EZH2mutation-positive individuals. These were shown to a panel
of five experienced dysmorphologists who assigned them to one of
three phenotypic categories: (1) “typical Weaver syndrome,” (2)
“possible Weaver syndrome,” or (3) “not Weaver syndrome.” If a
patient was assigned to the latter category and an alternative
diagnosis such as Sotos syndrome was suspected, this was noted.
Where possible, a majority score was used. However, if the results
from the five panelists were divergent, an average (median) score
was calculated andused.Thepatient’s agewhen thephotographwas
taken was recorded as <1, 1–5, 5–10, or >10 years.Molecular Studies
Four individuals (cases 19, 34, 40, and 46, Table SI) were identified
to have EZH2mutations through exome sequencing as previously
described [Snape et al., 2011; Tatton-Brown et al., 2011]. We
subsequently performed Sanger sequencing of the full coding
sequence and intron–exon boundaries of EZH2 in 431 additional
individuals from the COG study.We analyzed parental samples for
the specific EZH2 mutation identified in the proband, if samples
were available.Statistical Analyses
Independence of effects of phenotype group and age range was
analyzed using a 4 3 contingency table, examining for deviationFIG. 1. (a) Distribution of EZH2 missense and truncating mutations and
mutations (four where DNA from both parents was not available and onefrom the expected distribution (under the null hypothesis of
independence of effects) using Pearson’s chi-squared test (6df).RESULTS
EZH2 Mutational Spectrum
We identified 48 EZH2 mutations including 44 missense and 4
truncating variants (Fig. 1a). Variants were considered to be
pathogenic if they were de novo, familial, and clearly segregating
with the overgrowth phenotype or identical to a variant that had
been classified as pathogenic in another individual. Thirty-eight
variants fulfilled these criteria (Table SI). DNA was not available
from both parents of two individuals with truncating variants;
two individuals in whom the same amino acid residue, Arg684
and Glu148, had been substituted by a different amino acid as a de
novo event in at least one other individual; one individual with an
in-frame duplication and four individuals with missense variants.
Anadditional patient had inherited aHis618Tyrmissensemutation
from his father who did not have a clear overgrowth phenotype
(Table SI). However, none of these variants were identified in over
2,000 in-house exomes from controls or breast cancer patients nor
in over 6,000 exomes in the Exome variant server (http://evs.gs.
washington.edu/EVS/) and all the missense variants affected
highly conserved residues (Fig. 1b). Therefore, although we cannot
be unequivocally certain of pathogenicity because the penetrance/
expressivity of the mutations can be variable/mild, we considered it
likely that these variantswerecausativeof theovergrowthphenotype.
The 44 missense mutations were distributed throughout the
gene with some clustering in the highly conserved SET domain
(12/44, Fig. 1a). Two SET domain mutations, Arg684Cys and
Ser652Cys, were seen recurrently: the Arg684Cys mutation in
five unrelated individuals and the Ser652Cys mutation in
two unrelated individuals. Only four truncating mutations were
identified, all in the post-SET terminal exon, exon 20.(b) conservation of mutated residues in five cases with missense
where the mutation was inherited from an unaffected father).
TATTON-BROWN ET AL. 2975Clinical Features Associated With EZH2
Mutations
The typical Weaver syndrome facial gestalt can be subtle and
challenging to recognize. Among the 43 EZH2 mutation-
positive individuals in whom facial photographs were assessed
and categorized, 20 were assigned to group 1 (classic Weaver
syndrome), 11 to group 2 (possible Weaver syndrome) and 12
to group 3 (not typical for Weaver syndrome). In group 1, 10
individuals were at least 1 year and one individual was >10 years
(with five and four individuals 1–5 years and 5–10 years, respec-
tively). In group 2, one individual was<1 year, four were 1–5 years,
two were 5–10 years, and four were>10 years and in group 3 there
were no individuals who were <1 year, three were 1–5 years, one
was 5–10 years, and eight were>10 years (Fig. 2). This distribution
of ages and phenotypic group represented a significant excess of
younger cases in group 1 and older cases in group 3 (x2¼ 19.6,
P¼ 0.003 [6df]).
Facial features that characterized the 31EZH2mutation-positive
individuals considered to have classic and possible Weaver syn-
drome included ocular hypertelorism, almond shaped palpebral
fissures, a broad forehead, and a pointed, “stuck-on” chin with
horizontal skin crease and, in early childhood, large, fleshy ears, and
retrognathia (Fig. 3). However, while those individuals with classic
Weaver syndrome generally had all the listed features, individuals
with possible Weaver syndrome had some but not all. Among the
third “not Weaver syndrome” category, five individuals were
thought to have Sotos syndrome and four were not considered
to be dysmorphic. Additional, alternative, diagnoses proposed for
category 3patients includedKabuki syndromeandPeho syndrome,
each suggested by one panelist for one affected individual.
TheEZH2-related growthprofile. Information regardingbirth
weight was available for 39 babies: 22 females and 17 males. Only
38% (15/39, including 11 females and fourmales) EZH2mutation-
positive babies had a birth weight greater than two standard
deviations above the mean (þ2 SDs) with a median birth weight
ofþ1.3 SDs and a range of1.6 toþ4.6 SDs. Birth length is likely to
be a better correlate of an EZH2 mutation with EZH2 mutation-
positive babies frequently described as long and skinny. Unfortu-
nately, however, length is not always measured at birth and, even
when it is, parental recall is not as accurate as for weight. However,FIG. 2. Distribution of age and (facial) phenotypic groups.of the 18 babies with EZH2mutations and a birth length recorded,
12 had a length greater than 2 SD above the mean with an overall
range of 0.5 to þ4.9 SDs (Table SI).
Information regarding subsequent growth (height and head
circumference) was available for 45 EZH2mutation-positive indi-
viduals of whomnine were adults (>18 years) and 36 were children
(with ages between 0.4 and16.6 years and amedian age of 3.5 years).
Thirty-five of the children and six of the adults [in total 41/45
(91%)] had a height at least 2 SD above themean and in 14 children
and 2 adults the height was at least þ4 SDs (Fig. 4a, and Table SI).
Included amongst the four individuals whose height was less than
þ2 SDs, were three adults who were reported to be tall as young
children: case 4was overgrownuntil she developed a severe scoliosis
at the age of 18 months for which she subsequently required spinal
surgery as a teenager; the height of case 42 was 5.7 SDs above the
mean until the age of 3 after which growth velocity decelerated for
no apparent reason and case 3 was reported to be tall as a child but
information from childhood was unfortunately not available. In
contrast to height, head circumference measurements in 40 EZH2
mutation-positive children and adults ranged from 0.9 to
þ5.5 SDs with a median value ofþ1.8 SDs (Fig. 4b, and Table SI).
Most EZH2 mutation-positive individuals have a mild intel-
lectual disability. Amongst the 45 EZH2 mutation-positive
individuals where information on intellect was provided, the ma-
jority had an intellectual disability (37/45, 82%) but this was most
frequently mild (21/37, 57%). Twelve individuals had a moderate
intellectual disability and only two had a severe disability. In
addition, two individuals were said to have an intellectual disability
but the degree of impairment was not provided. Eight individuals
were reported to have normal intelligence, two individuals were
considered too young to be able to assess the degree of intellectual
impairment and no information was available for one individual.
Additional EZH2-associated clinical features. Poor coordina-
tion, often manifesting as clumsiness, was reported in 80% (28/35) of
EZH2mutation-positive individuals. Hypotonia and hypertoniawere
reported in 44% (18/41) and 28% (11/39) of EZH2mutation-positive
individuals, respectively, with a mixed picture of central hypotonia
and peripheral hypertonia reported in three affected individuals.
Additional clinical issues frequently reported included soft, doughy
skin (49%, 17/35); camptodactyly sometimes in combination with
additional joint contractures (45%, 17/38); hoarse, low-pitched cry
(37%, 10/27), and umbilical hernia (43%, 17/40, Table SI). It is
noteworthy that 8 of the 17 individuals with umbilical hernia
required surgical repair. Although not specifically solicited on either
the general or EZH2-specific questionnaire, flexion of the proximal
andhyperextension of the distal interphalangeal joints (analogous to a
mild boutonniere deformity) was identified through clinical exami-
nation of five affected adults. This deformity was not associated with
any detriment to function butmay be a useful diagnostic clue in older
EZH2 mutation-positive individuals.
Tumors occur, but not at high frequency, in EZH2 mutation-
positive individuals. Tumors were reported in only two EZH2
mutation-positive individuals: case 45 with a Glu745Lys missense
mutation and a lymphoma diagnosed at the age of 13 years and case
31 with an Ala682Thrmutation, who developed acute lymphoblas-
tic leukemia and neuroblastoma both at 13 months (Table SI).
Despite the association between somatic inactivating mutations
FIG. 3. Facial appearance of EZH2 mutation-positive individuals at (a) less than 1 year of age; (b) ages 1–5 years; (c) 5–10 years of age;
(d) teenage/adults.
2976 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aand chronic hematological malignancies, none of the latter were
reported amongst the 48 EZH2 mutation-positive individuals.
Imaging investigations in EZH2 mutation-positive Weaver
syndrome. Osseous maturation was only assessed in 25
EZH2 mutation-positive individuals but was advanced in all. Of
interest, a discrepancy between the carpal and phalangeal bone
maturation, with greater maturation reported for the carpal
bones, was recorded for three affected individuals. However, this
may be anunderestimate of the number ofEZH2mutation-positive
individuals with a carpal/phalangeal bone age discrepancy as details
additional to bone and chronological age were not requested on the
clinical questionnaires.
Nine EZH2mutation-positive individuals, in whom brain imag-
ing had been undertaken, had abnormal studies including four with
isolated ventriculomegaly; one individual with ventriculomegalyand periventricular leukomalacia and four individuals each with
either periventricular leukomalacia; pachygyria, and polymicrogy-
ria; a small infracted area in the cerebellum or a persistent cavum
septum pellucidum (Table SI).
Other clinical features. Other clinical features reported in
more than one but less than 10 EZH2mutation-positive individual
are shown in Table I. Until greater numbers of EZH2 mutation-
positive individuals are ascertained, it is not clear which of these
features are true EZH2 associations and which are coincidental,
particularly for features that are common in the general population.DISCUSSION
Through the identification of 48 EZH2mutation-positive individ-
ualswehave demonstrated thatmissensemutations are the primary
FIG. 4. Distribution of (a) height and (b) head circumference in
EZH2 mutation-positive individuals at varying ages.
TABLE I. Clinical Features Described in At Least Two But Less Than
10 EZH2 Mutation-Positive Individuals
Skeletal abnormalities
Clinodactyly 9
Scoliosis 6
Talipes equinovarus 5
Pectus excavatum/carinatum 4
Behavioral issues
Temper tantrums 3
Attention deficit 2
Genito-urinary abnormalities
Hydrocele 2
Congenital cardiac abnormalities
VSD 2
Ophthalmological abnormalities
Hypermetropia 3
Strabismus 2
Cutaneous
Hemangioma 4
Cafe´ au lait macule 2
Hearing loss 2
Cleft palate 2
Tumorsa 2
VSD, ventricular septal defect.
aTwo EZH2 mutation-positive individuals but with three tumors: neuroblastoma, ALL, and
lymphoma.
TATTON-BROWN ET AL. 2977EZH2mutationalmechanism inWeaver syndrome, present in over
90% of EZH2 mutation-positive individuals. To date, only four
truncating mutations have been identified, all within the terminal
exon, and therefore likely escape nonsense mediated RNA decay
and result in a truncated protein that retains the SET domain. The
predominance of missense mutations and the terminal location of
the truncating mutations suggest that simple EZH2 haploinsuffi-
ciency is unlikely to be the cause of Weaver syndrome. This is
corroborated by phenotypic data published for five cases with
deletions encompassing EZH2 where tall stature or overgrowth
is not reported although the authors have recently been informedof
one casewith tall stature and a 1.2Mbdeletion encompassingEZH2
(http://decipher.sanger.ac.uk/). Functional studies to investigate
themechanism of pathogenesis would be of interest, particularly as
the EZH2 mutational spectrum in Weaver syndrome differs from
the somatic mutational profile in hematological malignancies.
The clinical features associatedwithEZH2mutations are variable
and rather non-specific, and clinical diagnosis is therefore chal-
lenging. Less than half (47%) of the EZH2 mutation-positive
individuals were considered to have the classic Weaver syndrome
facial gestalt. However, it is noteworthy that the distribution of
ages in the group 1 compared with group 3 are very different with
over-representation of individuals <1 year of age in group 1 and
individuals >10 years of age in group 3. This age distribution
suggests that the facial phenotype is more easily recognized in
younger childhood, that there is greater familiarity with theWeaver
syndrome facial gestalt in this age range, or both. The data also
suggest that reviewof photographs at younger agesmay be helpful ifa diagnosis of Weaver syndrome is being considered in older
children or adults. The presence of additional features may also
be helpful. Tall stature, with a height at least 2 SDs above the mean,
is the most consistent EZH2-related clinical feature, present in
90% of affected individuals. Intellectual disability is also com-
mon, present in 80%, but can be very mild. Unfortunately both
features are non-specific and generally common, which limits their
utility as discriminating clinical features of Weaver syndrome.
More specific, but less frequent EZH2-related associations of
Weaver syndrome, identified in 30–50% of affected individuals,
include camptodactyly, hoarse, low cry, and soft, doughy skin.
Many of these features are present in the neonatal period/early
childhood and later resolve; they may be missed if a detailed
neonatal/early childhood history is unavailable.
Five of the 48 individuals in our study were considered to have
the facial features of Sotos syndrome, exemplifying the consider-
able clinical overlap between these two overgrowth conditions
(Table II). The facial features associated withNSD1mutations are
more distinctive than those of EZH2, and increased head circum-
ference is more characteristic of NSD1 mutations than EZH2
mutations. However, robust clinical differentiation between these
two conditions is not possible and thus NSD1 mutation analysis
should also be considered if EZH2 testing is negative, and vice
versa.Multi-gene testing, for example bynext-generation sequenc-
ing targeted gene or exome assays, will be the optimal analysis
allowing both genes to be analyzed.
The identification of constitutional EZH2 mutations as a
cause of Weaver syndrome has provided an objective means of
TABLE II. Molecular and Phenotypic Similarities and Differences Between NSD1-Positive Sotos Syndrome and EZH2-Positive Weaver
Syndrome
Overgrowth
syndrome
Causative
gene
Growth profile in
mutation-positive individualsa Intellectual disability Facial appearance
Associated clinical
features
Weaver syndrome EZH2 "bHt and OFC 40% None 20% Frontal bossing, round face,
hypertelorism. Large,
fleshy ears, retrognathia and
“stuck-on chin” in early
childhood
Camptodactyly
"Ht 50% Mild 50% Hoarse cry
"OFC 5% Moderate 25% Umbilical hernia
Not overgrown 5% Severe 5% Soft, doughy skin
Sotos syndromec NSD1 "Ht and OFC 50% None 5% Frontal bossing, dolicocephalic,
down slanting palpebral
fissures and malar flushing in
childhood
Congenital heart
anomalies
"Ht 20% Mild 30% Scoliosis
"OFC 20% Moderate 45–50% Renal abnormalities
Not overgrown 10% Severe 20% Seizures
aThe numbers are represented as approximate percentages of affected individuals.
bData from Tatton-Brown et al 2005b.
cThe arrow represents an increase of at least þ2 standard deviations.
Abbreviations, Ht, height; OFC, occipito-frontal circumference; SD, standard deviations.
2978 AMERICAN JOURNAL OF MEDICAL GENETICS PART Adiagnosing a frequently subtle condition, but there is stillmuch to
learn. ThemolecularmechanismbywhichEZH2mutations result
in Weaver syndrome is unknown and the relationship between
the clinical manifestations of germline and somatic EZH2muta-
tions is intriguing. For example, three missense mutations
Gly159Arg, Arg684Cys, and Tyr733, have been reported somat-
ically in myeloid malignancies and were identified constitution-
ally in eight unrelated individuals in the current series. None of
these individuals has developed a malignancy although, in con-
trast to our series with constitutional mutations comprised
predominantly of affected children, the majority of individuals
with myeloid malignancies are typically >60 years. There are
currently very little data about the phenotype of individuals
with Weaver syndrome in late adulthood, but the available
evidence suggests they may be at increased risk of hematological
malignancies. Long-term follow-up studies should be able
to address this in due course but until these data are available
we would recommend clinical vigilance and investigation of
any potential tumor related symptoms rather than a specific
surveillance program. It would also be of interest to investigate
if any of the individuals with hematological malignancies in
whom somatic EZH2 mutations have been identified, in fact
have constitutional mutations and undiagnosed Weaver syn-
drome. Given the mild and subtle phenotype of Weaver syn-
drome, this is plausible and readily evaluated through analyses of
buccal DNA.
Although the current study has allowed characterization of the
EZH2-mutation phenotype and is, to our knowledge, the world’s
largest cohort, it is a small series. With genetic analysis becoming ever
more accessible, the number of individuals identified with an EZH2
mutation is likely to increase rapidly. Thiswill facilitate understanding
of the phenotype at all ages, genotype–phenotype associations and
more accurate prognostic information. In turn, this will allow optimal
management for individuals with Weaver syndrome.WEB RESOURCES
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